Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro

Retrovirology

Volumn 5, Issue , 2008, Pages

  Ayouba, Ahidjo ^a   Cannou, Claude ^a   Nugeyre, Marie Thérèse ^a   Barré Sinoussi, Françoise ^a   Menu, Elisabeth ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOOROMETHYL)PHENYL]ETHYL]PIPERAZINE; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENFUVIRTIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DRUG DERIVATIVE; GLYCOPROTEIN GP 41; HETEROCYCLIC COMPOUND; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NICOTINAMIDE; PEPTIDE C34; PEPTIDE FRAGMENT; PEPTIDE T20; PIPERAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD PLACENTA BARRIER; CANCER CELL CULTURE; CELL FREE SYSTEM; CELL FUSION; CELL TRANSFER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; MONOLAYER CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; TARGET CELL; TROPHOBLAST; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS STRAIN; VIRUS TRANSMISSION; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; CELL COMMUNICATION; CELL CULTURE; CELL LINE; CLASSIFICATION; COCULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL LINE; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; HETEROCYCLIC COMPOUNDS; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; NIACINAMIDE; PEPTIDE FRAGMENTS; PIPERAZINES; PLACENTA; RECEPTORS, CCR5; RECEPTORS, CXCR4; TROPHOBLASTS; VIRUS REPLICATION;

EID: 42349090888     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-31     Document Type: Article

References (62)

1. McDonald D Wu L Bohks SM KewalRamani VN Unutmaz D Hope TJ Recruitment of HIV and its receptors to dendritic cell-T cell junctions Science 2003, 300(5623):1295-1297. 10.1126/science.1084238 12730499
2. Piguet V Sattentau Q Dangerous liaisons at the virological synapse J Clin Invest 2004, 114(5):605-610. 514595 15343375
3. Rappocciolo G Piazza P Fuller CL Reinhart TA Watkins SC Rowe DT Jais M Gupta P Rinaldo CR DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes PLoS Pathog 2006, 2(7):e70. 1500807 16839201 10.1371/journal.ppat.0020070
4. Lagaye S Derrien M Menu E Coito C Tresoldi E Mauclere P Scarlatti G Chaouat G Barre-Sinoussi F Bomsel M Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection J Virol 2001, 75(10):4780-4791. 114233 11312350 10.1128/ JVI.75.10.4780-4791.2001
5. Newell ML Current issues in the prevention of mother-to-child transmission of HIV-1 infection Trans R Soc Trop Med Hyg 2006, 100(1):1-5. 10.1016/j.trstmh.2005.05.012 16214193
6. Gupta K Klasse PJ How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 2006, 3(2):e79. 1388058 16492075 10.1371/journal.pmed.0030079
7. Ganesh L Leung K Lore K Levin R Panet A Schwartz O Koup RA Nabel GJ Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies J Virol 2004, 78(21):11980-11987. 523246 15479838 10.1128/JVI.78.21.11980-11987.2004
8. Gupta P Balachandran R Ho M Enrico A Rinaldo C Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody J Virol 1989, 63(5):2361-2365. 250658 2704079
9. Connor EM Sperling RS Gelber R Kiselev P Scott G O'Sullivan MJ VanDyke R Bey M Shearer W Jacobson RL Jimenez E O'Neill E Bazin B Delfraissy JF Culnane M Coombs R Elkins M Moye J Stratton P Balsley J The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment N Engl J Med 1994, 331(18):1173-1180. 10.1056/ NEJM199411033311801 7935654
10. Abrams EJ Prevention of mother-to-child transmission of HIV--successes, controversies and critical questions AIDS Rev 2004, 6(3):131-143. 15595430
11. Newell ML Thorne C Antiretroviral therapy and mother-to-child transmission of HIV-1 Expert Rev Anti Infect Ther 2004, 2(5):717-732. 10.1586/14789072.2.5.717 15482235
12. Scarlatti G Mother-to-child transmission of HIV-1: Advances and controversies of the twentieth centuries AIDS Rev 2004, 6(2):67-78. 15332429
13. Magder LS Mofenson L Paul ME Zorrilla CD Blattner WA Tuomala RE LaRussa P Landesman S Rich KC Risk factors for in utero and intrapartum transmission of HIV J Acquir Immune Defic Syndr 2005, 38(1):87-95. 10.1097/00126334-200501010-00016 15608531
14. UNAIDS: Report on Global HIV/AIDS epidemic, Geneva Geneva, World Health Organization; 2005.
15. Guay LA Musoke P Fleming T Bagenda D Allen M Nakabiito C Sherman J Bakaki P Ducar C Deseyve M Emel L Mirochnick M Fowler MG Mofenson L Miotti P Dransfield K Bray D Mmiro F Jackson JB Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. [see comments] Lancet 1999, 354(9181):795-802. 10.1016/ S0140-6736(99)80008-7 10485720
16. Lallemant M Jourdain G Le Coeur S Kim S Koetsawang S Comeau AM Phoolcharoen W Essex M McIntosh K Vithayasai V A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. [see comments] New England Journal of Medicine 2000 Oct 5;343(14):982-91 2000 343(14):982-991. 11018164 10.1056/ NEJM200010053431401
17. Ayouba A Tene G Cunin P Foupouapouognigni Y Menu E Kfutwah A Thonnon J Scarlatti G Monny-Lobe M Eteki N Kouanfack C Tardy M Leke R Nkam M Nlend AE Barre-Sinoussi F Martin PM Nerrienet E Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon J Acquir Immune Defic Syndr 2003, 34(3):274-280. 10.1097/00126334-200311010-00003 14600571
18. Wainberg MA Friedland G Public health implications of antiretroviral therapy and HIV drug resistance. JAMA UNITED STATES 1998, 279(24):1977-1983. 10.1001/jama.279.24.1977 9643862
19. Clotet B Raffi F Cooper D Delfraissy JF Lazzarin A Moyle G Rockstroh J Soriano V Schapiro J Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: Consensus recommendations AIDS 2004, 18(8):1137-1146. 10.1097/ 00002030-200405210-00007 15166529
20. Kish-Catalone TM Lu W Gallo RC DeVico AL Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5 Antimicrob Agents Chemother 2006, 50(4):1497-1509. 1426989 16569870 10.1128/AAC.50.4.1497-1509.2006
21. Strizki JM Tremblay C Xu S Wojcik L Wagner N Gonsiorek W Hipkin RW Chou CC Pugliese-Sivo C Xiao Y Tagat JR Cox K Priestley T Sorota S Huang W Hirsch M Reyes GR Baroudy BM Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 Antimicrob Agents Chemother 2005, 49(12):4911-4919. 1315929 16304152 10.1128/AAC.49.12.4911-4919.2005
22. Deeks SG The risk of treatment versus the risk of HIV replication Lancet 2006, 367(9527):1955-1956. 10.1016/S0140-6736(06)68857-0 16782465
23. Veazey RS Springer MS Marx PA Dufour J Klasse PJ Moore JP Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor Nat Med 2005, 11(12):1293-1294. 10.1038/nm1321 16273102
24. Veazey RS Klasse PJ Schader SM Hu Q Ketas TJ Lu M Marx PA Dufour J Colonno RJ Shattock RJ Springer MS Moore JP Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion Nature 2005, 438(7064):99-102. 10.1038/nature04055 16258536
25. Lalezari J Goodrich J DeJesus E Lampiris H Gulick R Saag M Ridgway C McHale M van der Ryst E Mayer H Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and Canada: 14-18 February; Los Angeles. 2007:104LB.
26. David FJ Autran B Tran HC Menu E Raphael M Debre P Hsi BL Wegman TG Barre-Sinoussi F Chaouat G Human trophoblast cells express CD4 and are permissive for productive infection with HIV-1 Clinical & Experimental Immunology 1992, 88(1):10-16. 1563094 1554366
27. Lairmore MD Cuthbert PS Utley LL Morgan CJ Dezzutti CS Anderson CL Sedmak DD Cellular localization of CD4 in the human placenta. Implications for maternal-to-fetal transmission of HIV J Immunol 1993, 151(3);1673-1681. 8335951
28. Douglas GC Thirkill TL Sideris V Rabieh M Trollinger D Nuccitelli R Chemokine receptor expression by human syncytiotrophoblast J Reprod Immunol 2001, 49(2):97-114. 10.1016/S0165-0378(00)00083-8 11164896
29. Mognetti B Moussa M Croitoru J Menu E Dormont D Roques P Chaouat G HIV-1 co-receptor expression on trophoblastic cells from early placentas and permissivity to infection by several HIV-1 primary isolates Clin Exp Immunol 2000, 119(3):486-492. 1905586 10691921 10.1046/ j.1365-2249.2000.01149.x
30. Maldonado-Estrada J Menu E Roques P Vaslin B Dautry-Varsat A Barre-Sinoussi F Chaouat G Predominant intracellular expression of CXCR4 and CCR5 in purified primary trophoblast cells from first trimester and term human placentae Am J Reprod Immunol 2003, 50(4):291-301. 10.1034/ j.1600-0897.2003.00084.x 14672331
31. Dolcini G Derrien M Chaouat G Barre-Sinoussi F Menu E Cell-free HIV type 1 infection is restricted in the human trophoblast choriocarcinoma BeWo cell line, even with expression of CD4, CXCR4 and CCR5 AIDS Res Hum Retroviruses 2003, 19(10):857-864. 10.1089/088922203322493021 14585217
32. Vidricaire G Tardif MR Tremblay MJ The low viral production in trophoblastic cells is due to a high endocytic internalization of the human immunodeficiency virus type 1 and can be overcome by the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-1 J Biol Chem 2003, 278(18):15832-15841. 10.1074/jbc.M210470200 12604606
33. Derrien M Faye A Dolcini G Chaouat G Barre-Sinoussi F Menu E Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro J Virol 2005, 79(19):12304-12310. 1211513 16160157 10.1128/JVI.79.19.12304-12310.2005
34. Kfutwah AK Mary JY Nicola MA Blaise-Boisseau S Barre-Sinoussi F Ayouba A Menu E Tumour necrosis factor-alpha stimulates HIV-1 replication in single-cycle infection of human term placental villi fragments in a time, viral dose and envelope dependent manner Retrovirology 2006, 3:36. 1533858 16796744 10.1186/1742-4690-3-36
35. Yi Y Shaheen F Collman RG Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes J Virol 2005, 79(3):1480-1486. 544090 15650174 10.1128/ JVI.79.3.1480-1486.2005
36. Kliger Y Gallo SA Peisajovich SG Munoz-Barroso I Avkin S Blumenthal R Shai Y Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage J Biol Chem 2001, 276(2):1391-1397. 10.1074/ jbc.M004113200 11027678
37. Dimitrov DS Willey RL Sato H Chang LJ Blumenthal R Martin MA Quantitation of human immunodeficiency virus type 1 infection kinetics J Virol 1993, 67(4):2182-2190. 240333 8445728
38. Trouplin V Salvatori F Cappello F Obry V Brelot A Heveker N Alizon M Scarlatti G Clavel F Mammano F Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay J Virol 2001, 75(1):251-259. 113919 11119595 10.1128/JVI.75.1.251-259.2001
39. Dragic T Trkola A Thompson DA Cormier EG Kajumo FA Maxwell E Lin SW Ying W Smith SO Sakmar TP Moore JP A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5 Proc Natl Acad Sci U S A 2000, 97(10):5639-5644. 25881 10779565 10.1073/ pnas.090576697
40. Tsamis F Gavrilov S Kajumo F Seibert C Kuhmann S Ketas T Trkola A Palani A Clader JW Tagat JR McCombie S Baroudy B Moore JP Sakmar TP Dragic T Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry J Virol 2003, 77(9):5201-5208. 153966 12692222 10.1128/ JVI.77.9.5201-5208.2003
41. Melby T Despirito M Demasi R Heilek-Snyder G Greenberg ML Graham N HIV-1 Coreceptor Use in Triple-Class Treatment-Experienced Patients: Baseline Prevalence, Correlates, and Relationship to Enfuvirtide Response J Infect Dis 2006, 194(2):238-246. 10.1086/504693 16779731
42. Hendrix CW Collier AC Lederman MM Schols D Pollard RB Brown S Jackson JB Coombs RW Glesby MJ Flexner CW Bridger GJ Badel K MacFarland RT Henson GW Calandra G Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection J Acquir Immune Defic Syndr 2004, 37(2):1253-1262. 10.1097/ 01.qai.0000137371.80695.ef 15385732
43. Flomenberg N DiPersio J Calandra G Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells Acta Haematol 2005, 114(4):198-205. 10.1159/000088410 16269859
44. Wild C Greenwell T Shugars D Rimsky-Clarke L Matthews T The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure AIDS Res Hum Retroviruses 1995, 11(3):323-325. 7786578
45. Lawless MK Barney S Guthrie KI Bucy TB Petteway SR Jr. Merutka G HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41 Biochemistry 1996, 35(42):13697-13708. 10.1021/bi9606962 8885850
46. Kliger Y Shai Y Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation J Mol Biol 2000, 295(2):163-168. 10.1006/ jmbi.1999.3368 10623516
47. Miller MD Geleziunas R Bianchi E Lennard S Hrin R Zhang H Lu M An Z Ingallinella P Finotto M Mattu M Finnefrock AC Bramhill D Cook J Eckert DM Hampton R Patel M Jarantow S Joyce J Ciliberto G Cortese R Lu P Strohl W Schleif W McElhaugh M Lane S Lloyd C Lowe D Osbourn J Vaughan T Emini E Barbato G Kim PS Hazuda DJ Shiver JW Pessi A A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope Proc Natl Acad Sci U S A 2005, 102(41):14759-14764. 1253587 16203977 10.1073/pnas.0506927102
48. Zhang X Nieforth K Lang JM Rouzier-Panis R Reynes J Dorr A Kolis S Stiles MR Kinchelow T Patel IH Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition Clin Pharmacol Ther 2002, 72(1):10-19. 10.1067/ mcp.2002.125945 12152000
49. Alfsen A Bomsel M HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide J Biol Chem 2002, 277(28):25649-25659. 10.1074/jbc.M200554200 11940580
50. Harouse JM Bhat S Spitalnik SL Laughlin M Stefano K Silberberg DH Gonzalez-Scarano F Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide Science 1991, 253(5017):320-323. 10.1126/science.1857969 1857969
51. Blanco J Bosch B Fernandez-Figueras MT Barretina J Clotet B Este JA High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells J Biol Chem 2004, 279(49):51305-51314. 10.1074/ jbc.M408547200 15371410
52. Xu Y Zhang X Matsuoka M Hattori T The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41 FEBS Lett 2000, 487(2):185-188. 10.1016/S0014-5793(00)02336-X 11150506
53. Howard OM Korte T Tarasova NI Grimm M Turpin JA Rice WG Michejda CJ Blumenthal R Oppenheim JJ Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function J Leukoc Biol UNITED STATES 1998, 64(1):6-13. 9665268
54. Su SB Gong WH Gao JL Shen WP Grimm MC Deng X Murphy PM Oppenheim JJ Wang JM T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor Blood 1999, 93(11):3885-3892. 10339497
55. Baldwin CE Berkhout B Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein Retrovirology 2006, 3:84. 1698932 17134507. 10.1186/1742-4690-3-84
56. Cohan D Feakins C Wara D Petru A McNicholl I Schillinger D Lu J Kuritzkes D Deeks SG Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen AIDS 2005, 19(9):989-990. 10.1097/01.aids.0000171417.84162.af 15905684
57. Brennan-Benson P Pakianathan M Rice P Bonora S Chakraborty R Sharland M Hay P Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta AIDS 2006, 20(2):297-299. 10.1097/01.aids.0000200535.02232.1b 16511429
58. Wensing AM Boucher CA van Kasteren M van Dijken PJ Geelen SP Juttmann JR Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir AIDS 2006, 20(10):1465-1467. 10.1097/01.aids.0000233587.94961.4f 16791028
59. Trowsdale J Travers P Bodmer WF Patillo RA Expression of HLA-A, -B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines J Exp Med 1980, 152(2 Pt 2):11s-17s. 6157763
60. Scarlatti G Leitner T Halapi E Wahlberg J Marchisio P Clerici-Schoeller MA Wigzell H Fenyo EM Albert J Uhlen M Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers Proc Natl Acad Sci U S A 1993, 90(5):1721-1725. 45951 8446584 10.1073/ pnas.90.5.1721
61. Menu E Reynes JM Muller-Trutwin MC Guillemot L Versmisse P Chiron M An S Trouplin V Charneau P Fleury H Barre-Sinoussi F Sainte Marie FF Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(5):481-487. 10225231
62. Weiss CD Barnett SW Cacalano N Killeen N Littman DR White JM Studies of HIV-1 envelope glycoprotein-mediated fusion using a simple fluorescence assay AIDS 1996, 10(3):241-246. 10.1097/00002030-199603000-00001 8882662